Ralf Schmid is a senior international life science executive with over 20 years of experience in finance, M&A, and licensing. As the CFO of F2G Ltd. , he leverages his expertise from previous roles at Nabriva Therapeutics, where he was instrumental in their Nasdaq IPO, and Sandoz. He holds a masters in finance and economics from Otto-Friedrich-Universität Bamberg.
Originally from Germany and now an Austrian resident, Ralf maintains a keen interest in the broader European life sciences community. He follows organizations like LISAvienna, a network supporting the life sciences hub in Vienna, where he was previously based with Nabriva Therapeutics AG.
Unique fact: He played a pivotal role in leading the successful spin-off of Nabriva Therapeutics from Sandoz and its subsequent public listing on Nasdaq.
Read the full overview →Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.
Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.